Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030 Report Highlights:
Hitherto, 3 oncolytic virus immunotherapies, namely Oncorine (H101), Imlygic (Talimogene laherparepvec), and teserpaturev (G47?; Delytact), have been approved over the preceding decennium for the treatment of different types of cancer like head and neck cancer, melanoma and malignant glioma. However, it is expected that the domain will observe many more approvals in the upcoming years because of that fact that a handful of advanced oncolytic virus immunotherapies such as Oncos 102, CAN-2409, Pelareorep, CG070, VG161 have received designations like Fast Track, Orphan Drug, PRIME from regulatory agencies, FDA and EMA.
In the clinical field, oncolytic viruses are at the forefront of innovative research and therapeutic development. These viruses, carefully engineered or selected for their innate oncolytic properties, are designed to infiltrate cancer cells, replicate within them, and induce their destruction while simultaneously stimulating an immune response. Moreover, as the sphere of oncolytic virus immunotherapy surpasses the confines of laboratories and clinical trials, its journey into the commercial arena is characterized by an involvement of pharma companies that will aid to shape its trajectory in the global cancer treatment landscape.
The triumph of other immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, has generated considerable interest in harnessing the immune system to fight cancer. Oncolytic virus immunotherapy complements these approaches by utilizing viruses to stimulate an immune response against cancer cells. The positive outcomes from these immunotherapies have fueled interest in leveraging the immune system to combat cancer, leading to increased exploration of oncolytic virus immunotherapy as a complementary and synergistic approach.
On that account, multiple studies are ongoing in the clinical pipeline which comprise the combinations of oncolytic viruses with different types of antibodies targeting immune checkpoint receptors such as delolimogene mupadenorepvec with atezolizumab, OH2 injection, with or without irinotecan or HX008, ADV/HSV-tk with Pembrolizumab, for the treatment of patients suffering from wide array of cancer subtypes such as pancreatic cancer, Gastrointestinal Cancer, breast cancer etc.
Competition from the involvement of multitudinous pharmaceutical companies such as Merck, Bristol-Myers Squibb, Astellas Pharma, Roche, Lokon Pharma, NRG oncology, CG oncology, Genemedicine, Binhui Biopharmaceutical Barinthus Biotherapeutics, TILT Biotherapeutics, Genelux Corporation, Replimune, and Candel Therapeutics have created wave in the commercial market of oncolytic virus immunotherapy. As a result, the clinical development landscape will observed several pharmaceuticals companies commencing research in order to understand the oncolytic virus mode of actions which will aid to develop advanced and innovative oncolytic virus immunotherapy with least possible side effects.
It is projected that the market of oncolytic virus immunotherapy is poised to expand and multiply further in the forthcoming years due to the augmenting government regulatory approvals in conjugation with snow balling investments, collaborations and partnerships in the pharmaceutical sector. As of May 2024, the oncolytic virus is crowded by usage of different types of oncolytic virus like herpes simplex type-1 virus (HSV-1) or adenoviruses with or without chemotherapy, monoclonal antibodies directing against PD-1 and PD-L1 receptors, therapeutic peptide vaccines or nanoparticles in order to optimize delivery and performance for cancer treatments.
Currently, the US remains the market leader of the market as evident from rising collaborations, advancement and government bestow. The synergy between these clinical and commercial aspects propels the field forward, offering new expectation to cancer patients and shaping the future of cancer treatment. Continuous research, innovation, and collaboration are essential to sustaining this growth and realizing the full potential of oncolytic virus immunotherapy. As research further delves deeper into understanding the complexities of this innovative approach, there is optimism that oncolytic viruses will emerge as a valuable addition for cancer treatments, offering new avenues for improved outcomes and enhanced quality of life for patients.
Global Oncolytic Virus Immunotherapy Market Opportunity & Clinical Trials Insight 2030 Report Highlights:
- Global Oncolytic Virus Immunotherapy Therapy Market Opportunity: > USD 1.50 Billion By 2030
- Oncolytic Viruses Immunotherapies Clinical Trials By Company, Indication & Phase
- Comprehensive Insight On Oncolytic Virus Immunotherapies In Clinical Trials: > 180 Therapies
- FDA & EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME
- Patent Analysis Therapies in Clinical Trials
- IMLYGIC, Oncorine, Delytact: Availability, Dosage and Price Analysis
- Platforms Used For Developing Advanced Oncolytic Virus Immunotherapy
Hitherto, 3 oncolytic virus immunotherapies, namely Oncorine (H101), Imlygic (Talimogene laherparepvec), and teserpaturev (G47?; Delytact), have been approved over the preceding decennium for the treatment of different types of cancer like head and neck cancer, melanoma and malignant glioma. However, it is expected that the domain will observe many more approvals in the upcoming years because of that fact that a handful of advanced oncolytic virus immunotherapies such as Oncos 102, CAN-2409, Pelareorep, CG070, VG161 have received designations like Fast Track, Orphan Drug, PRIME from regulatory agencies, FDA and EMA.
In the clinical field, oncolytic viruses are at the forefront of innovative research and therapeutic development. These viruses, carefully engineered or selected for their innate oncolytic properties, are designed to infiltrate cancer cells, replicate within them, and induce their destruction while simultaneously stimulating an immune response. Moreover, as the sphere of oncolytic virus immunotherapy surpasses the confines of laboratories and clinical trials, its journey into the commercial arena is characterized by an involvement of pharma companies that will aid to shape its trajectory in the global cancer treatment landscape.
The triumph of other immunotherapies, such as checkpoint inhibitors and CAR-T cell therapies, has generated considerable interest in harnessing the immune system to fight cancer. Oncolytic virus immunotherapy complements these approaches by utilizing viruses to stimulate an immune response against cancer cells. The positive outcomes from these immunotherapies have fueled interest in leveraging the immune system to combat cancer, leading to increased exploration of oncolytic virus immunotherapy as a complementary and synergistic approach.
On that account, multiple studies are ongoing in the clinical pipeline which comprise the combinations of oncolytic viruses with different types of antibodies targeting immune checkpoint receptors such as delolimogene mupadenorepvec with atezolizumab, OH2 injection, with or without irinotecan or HX008, ADV/HSV-tk with Pembrolizumab, for the treatment of patients suffering from wide array of cancer subtypes such as pancreatic cancer, Gastrointestinal Cancer, breast cancer etc.
Competition from the involvement of multitudinous pharmaceutical companies such as Merck, Bristol-Myers Squibb, Astellas Pharma, Roche, Lokon Pharma, NRG oncology, CG oncology, Genemedicine, Binhui Biopharmaceutical Barinthus Biotherapeutics, TILT Biotherapeutics, Genelux Corporation, Replimune, and Candel Therapeutics have created wave in the commercial market of oncolytic virus immunotherapy. As a result, the clinical development landscape will observed several pharmaceuticals companies commencing research in order to understand the oncolytic virus mode of actions which will aid to develop advanced and innovative oncolytic virus immunotherapy with least possible side effects.
It is projected that the market of oncolytic virus immunotherapy is poised to expand and multiply further in the forthcoming years due to the augmenting government regulatory approvals in conjugation with snow balling investments, collaborations and partnerships in the pharmaceutical sector. As of May 2024, the oncolytic virus is crowded by usage of different types of oncolytic virus like herpes simplex type-1 virus (HSV-1) or adenoviruses with or without chemotherapy, monoclonal antibodies directing against PD-1 and PD-L1 receptors, therapeutic peptide vaccines or nanoparticles in order to optimize delivery and performance for cancer treatments.
Currently, the US remains the market leader of the market as evident from rising collaborations, advancement and government bestow. The synergy between these clinical and commercial aspects propels the field forward, offering new expectation to cancer patients and shaping the future of cancer treatment. Continuous research, innovation, and collaboration are essential to sustaining this growth and realizing the full potential of oncolytic virus immunotherapy. As research further delves deeper into understanding the complexities of this innovative approach, there is optimism that oncolytic viruses will emerge as a valuable addition for cancer treatments, offering new avenues for improved outcomes and enhanced quality of life for patients.
1. INTRODUCTION TO ONCOLYTIC VIRUS THERAPY
1.1 Overview
1.2 Need of Oncolytic Virus Immunotherapy
2. GLOBALLY APPROVED ONCOLYTIC VIRUS IMMUNOTHERAPIES
2.1 Commercially Approved Therapies
2.2 FDA & EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME
3. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPIES CLINICAL TRIALS OVERVIEW
3.1 By Phase
3.2 By Country
3.3 By Company
3.4 By Indication
3.5 By Priority Status
3.6 Patient Segment
4. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET TREND & DEVELOPMENTS
4.1 Current Market Outline
4.2 Future Market Forecast
5. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET TRENDS BY REGION
5.1 South Korea
5.2 Japan
5.3 US
5.4 Europe
5.5 UK
5.6 China
5.7 Australia
6. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET TRENDS BY INDICATIONS
6.1 Melanoma
6.2 Head & Neck Cancer
6.3 Glioma
6.4 Pancreatic Cancer
6.5 Ovarian Cancer
6.6 Lymphoma
6.7 Lung Cancer
6.8 Breast Cancer
6.9 Prostate Cancer
6.10 Hepatocellular carcinoma
7. GLOBAL ONCOLYTIC VIRUSES IMMUNOTHERAPIES CLINICAL TRIALS BY COMPANY, INDICATION & PHASE
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-III
7.7 Registered
8. MARKETED ONCOLYTIC VIRUSES IMMUNOTHERAPIES CLINICAL INSIGHT
9. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY - AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Imlygic
9.1.1 Overview & Patent Insights
9.1.2 Pricing & Dosage
9.2 Oncorine (H101)
9.2.1 Overview
9.2.2 Pricing & Dosage
9.3 Delytact
9.3.1 Overview
9.3.2 Pricing & Dosage
10. PLATFORMS USED FOR DEVELOPING ADVANCED ONCOLYTIC VIRUS IMMUNOTHERAPY
10.1 KaliVir VET Backbone Technology
10.2 Calidi’s Platform Technology
10.3 RenovoRx TAMP Platform
10.4 ValoTx PeptiCRAd
10.5 ValoTx PeptiVAX / PeptiENV / PeptiBAC
10.6 Transgene’s Invir.IO Platform
10.7 Transgene’s myvac Platform
10.8 Imugene’s CF33 Technology
10.9 EpicentRx AdAPT Platform
10.10 Genelux’s Choice Discovery Platform
11. ONCOLYTIC VIRUS IMMUNOTHERAPY COMBINATIONS WITH OTHER THERAPEUTIC AGENTS
11.1 Oncolytic Virus Immunotherapy with Nano materials
11.2 Oncolytic Virus Immunotherapy with Chemotherapeutic Drugs
11.3 Oncolytic Virus Immunotherapy with Peptides
11.4 Oncolytic Virus Immunotherapy with Targeted Immunotherapies
12. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET DYNAMICS
12.1 Market Drivers
12.2 Market Challenges
13. COMPETITIVE LANDSCAPE
13.1 AdCure Bio
13.2 Beijing SyngenTech
13.3 BioVex Inc. (Amgen)
13.4 Calidi Biotherapeutics
13.5 Genelux Corporation
13.6 Immvira Pharma
13.7 Jennerex Biotherapeutics
13.8 KaliVir
13.9 Lokon Pharma
13.10 Oncolys BioPharma
13.11 PsiOxus Therapeutics (Akamis Bio)
13.12 Seneca Therapeutics
13.13 Shanghai Sunway Biotech
13.14 Takara Bio
13.15 TILT Biotherapeutics
13.16 Transgene
13.17 Virogin Biotech
Table 2-1: Approved Oncolytic Virus Immunotherapies
Table 5-1: US – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 5-2: Europe – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-1: Melanoma – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-2: Head & Neck Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-3: Glioma – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-4: Pancreatic Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-5: Ovarian Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-6: Lung Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-7: Breast Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 9-1: Imlygic - Recommended Dose & Schedule
1.1 Overview
1.2 Need of Oncolytic Virus Immunotherapy
2. GLOBALLY APPROVED ONCOLYTIC VIRUS IMMUNOTHERAPIES
2.1 Commercially Approved Therapies
2.2 FDA & EMA Designations: Breakthrough Therapy, Fast Track, Orphan, PRIME
3. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPIES CLINICAL TRIALS OVERVIEW
3.1 By Phase
3.2 By Country
3.3 By Company
3.4 By Indication
3.5 By Priority Status
3.6 Patient Segment
4. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET TREND & DEVELOPMENTS
4.1 Current Market Outline
4.2 Future Market Forecast
5. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET TRENDS BY REGION
5.1 South Korea
5.2 Japan
5.3 US
5.4 Europe
5.5 UK
5.6 China
5.7 Australia
6. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET TRENDS BY INDICATIONS
6.1 Melanoma
6.2 Head & Neck Cancer
6.3 Glioma
6.4 Pancreatic Cancer
6.5 Ovarian Cancer
6.6 Lymphoma
6.7 Lung Cancer
6.8 Breast Cancer
6.9 Prostate Cancer
6.10 Hepatocellular carcinoma
7. GLOBAL ONCOLYTIC VIRUSES IMMUNOTHERAPIES CLINICAL TRIALS BY COMPANY, INDICATION & PHASE
7.1 Research
7.2 Preclinical
7.3 Phase-I
7.4 Phase-I/II
7.5 Phase-II
7.6 Phase-III
7.7 Registered
8. MARKETED ONCOLYTIC VIRUSES IMMUNOTHERAPIES CLINICAL INSIGHT
9. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY - AVAILABILITY, DOSAGE & PRICE ANALYSIS
9.1 Imlygic
9.1.1 Overview & Patent Insights
9.1.2 Pricing & Dosage
9.2 Oncorine (H101)
9.2.1 Overview
9.2.2 Pricing & Dosage
9.3 Delytact
9.3.1 Overview
9.3.2 Pricing & Dosage
10. PLATFORMS USED FOR DEVELOPING ADVANCED ONCOLYTIC VIRUS IMMUNOTHERAPY
10.1 KaliVir VET Backbone Technology
10.2 Calidi’s Platform Technology
10.3 RenovoRx TAMP Platform
10.4 ValoTx PeptiCRAd
10.5 ValoTx PeptiVAX / PeptiENV / PeptiBAC
10.6 Transgene’s Invir.IO Platform
10.7 Transgene’s myvac Platform
10.8 Imugene’s CF33 Technology
10.9 EpicentRx AdAPT Platform
10.10 Genelux’s Choice Discovery Platform
11. ONCOLYTIC VIRUS IMMUNOTHERAPY COMBINATIONS WITH OTHER THERAPEUTIC AGENTS
11.1 Oncolytic Virus Immunotherapy with Nano materials
11.2 Oncolytic Virus Immunotherapy with Chemotherapeutic Drugs
11.3 Oncolytic Virus Immunotherapy with Peptides
11.4 Oncolytic Virus Immunotherapy with Targeted Immunotherapies
12. GLOBAL ONCOLYTIC VIRUS IMMUNOTHERAPY MARKET DYNAMICS
12.1 Market Drivers
12.2 Market Challenges
13. COMPETITIVE LANDSCAPE
13.1 AdCure Bio
13.2 Beijing SyngenTech
13.3 BioVex Inc. (Amgen)
13.4 Calidi Biotherapeutics
13.5 Genelux Corporation
13.6 Immvira Pharma
13.7 Jennerex Biotherapeutics
13.8 KaliVir
13.9 Lokon Pharma
13.10 Oncolys BioPharma
13.11 PsiOxus Therapeutics (Akamis Bio)
13.12 Seneca Therapeutics
13.13 Shanghai Sunway Biotech
13.14 Takara Bio
13.15 TILT Biotherapeutics
13.16 Transgene
13.17 Virogin Biotech
Table 2-1: Approved Oncolytic Virus Immunotherapies
Table 5-1: US – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 5-2: Europe – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-1: Melanoma – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-2: Head & Neck Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-3: Glioma – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-4: Pancreatic Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-5: Ovarian Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-6: Lung Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 6-7: Breast Cancer – Ongoing Clinical Trials for Oncolytic Virus Immunotherapy
Table 9-1: Imlygic - Recommended Dose & Schedule
